BOHAI BIOTECH MCTL:
SCIENCE & TARGET LIBRARY
A personalised T-cell platform training immune cells against a curated combination of tumour-associated antigens. Developed through research at Tianjin Medical University โ explained in patient-readable terms.
analyticsAt a Glance
- check_circleTrains T cells against multiple tumour antigens simultaneously
- check_circleUses peptide-pulsed dendritic cells for antigen presentation
- check_circlePhase Ib trial combining with toripalimab in NSCLC
- check_circleInvestigational โ not an approved standard therapy
The Core Idea Behind MCTL
Instead of targeting one cancer marker, MCTL trains T cells against a personalised combination of tumour-associated antigen peptides โ reducing the risk of antigen-escape resistance common in single-target approaches.
โA curated target library means the therapy can be personalised to each patient's tumour antigen profile rather than applying a fixed single target to all patients.โ
Multi-Antigen Targeting
T cells are trained against several tumour-associated antigens โ such as MAGE family, survivin, WT1, NY-ESO-1, and others โ drawn from a curated reference library matched to the patient's tumour profile.
Dendritic Cell Bridge
Autologous dendritic cells are pulsed with the selected peptide combination. These cells act as antigen-presenting vehicles that activate and expand tumour-specific T cells in the laboratory.
How Bohai Biotech MCTL Is Manufactured
The manufacturing process is personalised to each patient's antigen profile.
- 1
Tumour Antigen Profiling
Pathology and biomarker review to identify which tumour-associated antigens from the reference library are expressed in the patient's cancer.
- 2
Leukapheresis
Peripheral blood drawn; T cells and monocytes (which become dendritic cells) are separated.
- 3
Dendritic Cell Preparation & Peptide Pulsing
Monocytes are matured into dendritic cells and loaded with the personalised combination of tumour-associated antigen peptides.
- 4
T-Cell Expansion
Dendritic cells are co-cultured with the patient's T cells, activating and expanding tumour-specific cytotoxic T lymphocytes to therapeutic numbers.
- 5
Reinfusion
Expanded MCTL cells are quality-tested and reinfused, often in combination with toripalimab.
The Published Clinical Evidence
The key published evidence for this platform is a Phase Ib trial in advanced NSCLC combining MCTL with toripalimab.
Phase Ib Trial: MCTL + Toripalimab in Advanced NSCLC
Published in Cancer Immunology, Immunotherapy (2026). 21 patients with advanced NSCLC received personalised peptide-pulsed dendritic cell-based MCTL combined with toripalimab as second-line therapy. The study reported manageable safety and encouraging early activity. It was single-arm and small โ results require confirmation in larger studies.
What the Evidence Does and Does Not Show
Early feasibility, acceptable safety, and encouraging disease control signals. It does not confirm superiority over standard care in a randomised trial. Patients should understand this distinction before making treatment decisions.
How Bohai Biotech MCTL Compares With Related Therapies
| Therapy | Mechanism | Status | Key Difference vs MCTL |
|---|---|---|---|
| CAR-T | Genetically engineers T cells to bind surface antigens | Approved (blood cancers) | Surface targets only; genetic engineering required |
| TIL Therapy | Expands naturally tumour-infiltrating T cells from resected tissue | Approved (melanoma); investigational elsewhere | Requires surgical tumour tissue; naturally occurring TCRs |
| TCR-T | Engineers T cells with TCR against one intracellular antigen | Investigational | Single antigen; genetic engineering; MCTL targets multiple antigens |
| DC Vaccine | Dendritic cells pulsed with antigens โ but not combined with T-cell expansion | Investigational | Vaccine only โ does not deliver pre-activated T cells |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If Bohai Biotech MCTL Is Relevant for Your Case?
CancerFax reviews your pathology, antigen profile, and prior treatment history to assess whether MCTL โ including the Bohai Biotech approach โ is a realistic next step for your diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.